lorediplon

Lorediplon is an investigational non‑benzodiazepine small‑molecule hypnotic of the pyrazolopyrimidine class that acts as a positive allosteric modulator of GABAA receptors with preferential activity at α1 subunit‑containing receptors, which mediate sleep‑promoting and sedative effects.[1][5][8] Developed originally by Ferrer as a longer‑acting alternative to existing non‑benzodiazepine hypnotics, lorediplon has shown dose‑dependent improvements in sleep onset and maintenance, preservation of sleep architecture, and a lack of significant next‑day residual effects in early‑phase clinical studies in patients with insomnia.[1][2][4][6] Despite completing Phase I and at least one Phase II trial in insomnia, the program has not progressed to approval and remains an unapproved research compound.[1][6][9]